Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

CBO: $345B In Savings From H.R. 3 Comes At Cost Of Fewer New Drugs

By John Wilkerson
October 11, 2019 at 6:29 PM
The Congressional Budget Office estimates that House Democrats’ bill to negotiating drug prices would save taxpayers $345 billion in six years, but that savings would come at the cost of 8 to 15 fewer drugs being invented over a decade -- FDA approves about 30 new drugs annually. CBO’s preliminary estimate of H.R. 3 is that brand drug makers revenues would be reduced by half a trillion dollars to $1 trillion. The House bill would direct HHS to negotiate prices...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.